Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, et al. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L). Lung Cancer 2022;168:38-45.
PMID: 35477147